Cardiff Oncology (CRDF) Expected to Release Earnings on Tuesday

Cardiff Oncology (NASDAQ:CRDF) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Cardiff Oncology to post earnings of ($0.17) per share and revenue of $0.0630 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Stock Down 3.5%

NASDAQ:CRDF opened at $0.81 on Tuesday. The firm has a market cap of $55.28 million, a PE ratio of -1.20 and a beta of 1.44. Cardiff Oncology has a 12 month low of $0.80 and a 12 month high of $3.80. The company’s 50-day moving average price is $1.35 and its two-hundred day moving average price is $1.70.

Insiders Place Their Bets

In other news, Director Gary W. Pace purchased 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average price of $1.22 per share, for a total transaction of $36,600.00. Following the completion of the acquisition, the director directly owned 1,356,376 shares in the company, valued at approximately $1,654,778.72. The trade was a 2.26% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mani Mohindru acquired 24,703 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $1.21 per share, with a total value of $29,890.63. Following the completion of the transaction, the chief executive officer owned 24,703 shares of the company’s stock, valued at approximately $29,890.63. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 8.50% of the company’s stock.

Institutional Trading of Cardiff Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brooklyn Investment Group acquired a new position in Cardiff Oncology during the 3rd quarter valued at about $26,000. Engineers Gate Manager LP acquired a new stake in shares of Cardiff Oncology during the 2nd quarter worth approximately $43,000. BNP Paribas Financial Markets grew its position in shares of Cardiff Oncology by 335.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock worth $49,000 after buying an additional 11,889 shares during the period. Raymond James Financial Inc. raised its stake in shares of Cardiff Oncology by 70.1% during the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock worth $49,000 after buying an additional 9,740 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after buying an additional 4,232 shares during the last quarter. 16.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on CRDF. Weiss Ratings cut shares of Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 21st. HC Wainwright lowered Cardiff Oncology from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Craig Hallum lowered Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research report on Wednesday, June 3rd. TD Cowen downgraded shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. Finally, Wall Street Zen downgraded shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cardiff Oncology presently has an average rating of “Hold” and a consensus price target of $7.50.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.